Current State of Targeted Therapy in Adult Langerhans Cell Histiocytosis and Erdheim-Chester Disease

Overview

Journal Target Oncol

Specialty Oncology

Date 2024 Jul 11

PMID 38990463

Authors

He Lin

Xin-Xin Cao

Affiliations

Soon will be listed here.

Abstract

The mitogen-activated protein kinase (MAPK) pathway is a key driver in many histiocytic disorders, including Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD). This has led to successful and promising treatment with targeted therapies, including BRAF inhibitors and MEK inhibitors. Additional novel inhibitors have also demonstrated encouraging results. Nevertheless, there are several problems concerning targeted therapy that need to be addressed. These include, among others, incomplete responsiveness and the emergence of resistance to BRAF inhibition as observed in other BRAF-mutant malignancies. Drug resistance and relapse after treatment interruption remain problems with current targeted therapies. Targeted therapy does not seem to eradicate the mutated clone, leading to inevitable relapes, which is a huge challenge for the future. More fundamental research and clinical trials are needed to address these issues and to develop improved targeted therapies that can overcome resistance and achieve long-lasting remissions.

Citing Articles

Recent advances in therapeutic strategies of Erdheim-Chester disease.

Doke R, Lokhande R, Chande K, Vinchurkar K, Prajapati B Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39836251 DOI: 10.1007/s00210-024-03769-2.

References

Emile J, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J . Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016; 127(22):2672-81. PMC: 5161007. DOI: 10.1182/blood-2016-01-690636. View

Goyal G, Tazi A, Go R, Rech K, Picarsic J, Vassallo R . International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. 2022; 139(17):2601-2621. PMC: 11022927. DOI: 10.1182/blood.2021014343. View

Tazi A, de Margerie C, Naccache J, Fry S, Dominique S, Jouneau S . The natural history of adult pulmonary Langerhans cell histiocytosis: a prospective multicentre study. Orphanet J Rare Dis. 2015; 10:30. PMC: 4438520. DOI: 10.1186/s13023-015-0249-2. View

Vassallo R, Ryu J, Schroeder D, Decker P, Limper A . Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med. 2002; 346(7):484-90. DOI: 10.1056/NEJMoa012087. View

Makras P, Yavropoulou M, Chatziioannou S, Anastasilakis A, Georgakopoulou D, Tsoli M . Efficacy of denosumab monotherapy among adults with Langerhans cell histiocytosis: A prospective clinical trial. Am J Hematol. 2023; 98(7):E168-E171. DOI: 10.1002/ajh.26936. View

Makras P, Tsoli M, Anastasilakis A, Thanou M, Kaltsas G . Denosumab for the treatment of adult multisystem Langerhans cell histiocytosis. Metabolism. 2017; 69:107-111. DOI: 10.1016/j.metabol.2017.01.004. View

Cao X, Li J, Zhao A, He T, Gao X, Cai H . Methotrexate and cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis: A single arm, single center, prospective phase 2 study. Am J Hematol. 2020; 95(9):E235-E238. DOI: 10.1002/ajh.25864. View

Chang L, Lang M, Lin H, Cai H, Duan M, Zhou D . Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis. Leukemia. 2024; 38(4):803-809. DOI: 10.1038/s41375-024-02174-1. View

Duan M, Han X, Li J, Zhang W, Zhu T, Han B . Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis: A single-center retrospective study. Leuk Res. 2016; 42:43-6. DOI: 10.1016/j.leukres.2016.01.012. View

10.

Goyal G, Abeykoon J, Hu M, Young J, Shah M, Bennani N . Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis. Am J Hematol. 2021; 96(5):E146-E150. PMC: 8044045. DOI: 10.1002/ajh.26119. View

11.

Zinn D, Grimes A, Lin H, Eckstein O, Allen C, McClain K . Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood. 2016; 128(20):2462-2465. PMC: 5114488. DOI: 10.1182/blood-2016-06-721993. View

12.

Sakamoto K, Kikuchi K, Sako M, Kato M, Takimoto T, Shioda Y . Pilot study to estimate the safety and effectiveness of hydroxyurea and methotrexate recurrent langerhans cell histiocytosis (LCH-HU-pilot). Medicine (Baltimore). 2022; 101(50):e31475. PMC: 9771280. DOI: 10.1097/MD.0000000000031475. View

13.

Goyal G, Shah M, Call T, Litzow M, Hogan W, Go R . Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease. JAMA Oncol. 2017; 3(9):1253-1256. PMC: 5824289. DOI: 10.1001/jamaoncol.2017.0041. View

14.

Haroche J, Amoura Z, Trad S, Wechsler B, Cluzel P, Grenier P . Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum. 2006; 54(10):3330-6. DOI: 10.1002/art.22165. View

15.

Goyal G, Heaney M, Collin M, Cohen-Aubart F, Vaglio A, Durham B . Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020; 135(22):1929-1945. DOI: 10.1182/blood.2019003507. View

16.

Haroche J, Charlotte F, Arnaud L, von Deimling A, Helias-Rodzewicz Z, Hervier B . High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012; 120(13):2700-3. DOI: 10.1182/blood-2012-05-430140. View

17.

Badalian-Very G, Vergilio J, Degar B, Macconaill L, Brandner B, Calicchio M . Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010; 116(11):1919-23. PMC: 3173987. DOI: 10.1182/blood-2010-04-279083. View

18.

Chakraborty R, Hampton O, Shen X, Simko S, Shih A, Abhyankar H . Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014; 124(19):3007-15. PMC: 4224195. DOI: 10.1182/blood-2014-05-577825. View

19.

Durham B, Lopez Rodrigo E, Picarsic J, Abramson D, Rotemberg V, De Munck S . Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med. 2019; 25(12):1839-1842. PMC: 6898787. DOI: 10.1038/s41591-019-0653-6. View

20.

Berres M, Lim K, Peters T, Price J, Takizawa H, Salmon H . BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014; 211(4):669-83. PMC: 3978272. DOI: 10.1084/jem.20130977. View